Notes
2018 US dollars
Reference
Wu B, et al. Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer. Therapeutic Advances in Medical Oncology 12: 5 May 2020. Available from: URL: https://doi.org/10.1177/1758835920916000
Rights and permissions
About this article
Cite this article
Atezolizumab cost effective in advanced triple-negative breast cancer?. PharmacoEcon Outcomes News 854, 7 (2020). https://doi.org/10.1007/s40274-020-6837-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6837-y